Nicotinic acetylcholine receptor antagonist (PubMed:35418867). Binds to muscle nicotinic acetylcholine receptor (nAChR) and inhibits acetylcholine from binding to the receptor, thereby impairing neuromuscular transmission (PubMed:35418867). Produces peripheral paralysis by blocking neuromuscular transmission at the postsynaptic site (PubMed:35418867). Induces concentration-dependent inhibition of indirect twitches and abolishes contractile responses of tissues to exogenous acetylcholine and carbachol, in the chick biventer cervicis nerve-muscle preparation at 100-300 nM (in vitro) (PubMed:35418867). Prior incubation of tissues with Indian polyvalent antivenom (1 ml/0.6 mg) prevents the neurotoxic effects at 100 nM (in vitro) (PubMed:35418867). Addition of Indian polyvalent antivenom (1 ml/0.6 mg) at the t90 time point does not reverse the neurotoxic effects (in vitro) (PubMed:35418867). Displays non-competitive antagonism of concentration-response curves to carbachol, with a pA2 of 8.01 (in vitro) (PubMed:35418867). Expressed by the venom gland. Constitutes approximately 1% of the whole venom protein content. Belongs to the snake three-finger toxin family. Short-chain subfamily. Type I alpha-neurotoxin sub-subfamily.